These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12832673)

  • 21. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK; Triller DM; Yong CS; Lodise TP
    Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemifloxacin.
    Lowe MN; Lamb HM
    Drugs; 2000 May; 59(5):1137-47; discussion 1148. PubMed ID: 10852645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis.
    Wilson R; Jones P; Schaberg T; Arvis P; Duprat-Lomon I; Sagnier PP;
    Thorax; 2006 Apr; 61(4):337-42. PubMed ID: 16449273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin.
    Lipsky BA; Unowsky J; Zhang H; Townsend L; Talbot GH
    Clin Ther; 1999 Jun; 21(6):954-65. PubMed ID: 10440620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology.
    Kemper P; Köhler D
    Am J Med; 1992 Apr; 92(4A):98S-102S. PubMed ID: 1316079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical contribution of the newer fluoroquinolones in acute bacterial exacerbation of chronic bronchitis].
    Niederman MS
    Medicina (B Aires); 1999; 59 Suppl 1():23-30. PubMed ID: 10436551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.
    Torrance G; Walker V; Grossman R; Mukherjee J; Vaughan D; La Forge J; Lampron N
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):499-520. PubMed ID: 10662396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
    DeAbate CA; Bettis R; Munk ZM; Fleming H; Munn NJ; Riffer E; Bagby B; Giguere G; Collins JJ
    Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis.
    Solèr M; Lode H; Baldwin R; Levine JH; Schreurs AJ; van Noord JA; Maesen FP; Zehrer M;
    Eur J Clin Microbiol Infect Dis; 2003 Mar; 22(3):144-50. PubMed ID: 12649711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of lomefloxacin in patients with acute exacerbation of chronic bronchitis (AECB) chronically treated with oral theophyllines.
    Melani AS; Pirrelli M; Sarlo F; Cantoni V;
    J Chemother; 2001 Dec; 13(6):628-34. PubMed ID: 11806624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis.
    Destache CJ; Dewan N; O'Donohue WJ; Campbell JC; Angelillo VA
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():107-13. PubMed ID: 10225580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validity of the St George's respiratory questionnaire at acute exacerbation of chronic bronchitis: comparison with the Nottingham health profile.
    Doll H; Duprat-Lomon I; Ammerman E; Sagnier PP
    Qual Life Res; 2003 Mar; 12(2):117-32. PubMed ID: 12639059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic therapy of exacerbations of chronic bronchitis.
    Niederman MS
    Semin Respir Infect; 2000 Mar; 15(1):59-70. PubMed ID: 10749551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bacterial exacerbation of chronic bronchitis: massive or long term antibiotic therapy?].
    Bürgi H
    Schweiz Med Wochenschr; 1970 Oct; 100(43):1846-8. PubMed ID: 5003997
    [No Abstract]   [Full Text] [Related]  

  • 36. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
    Ball P; Mandell L; Patou G; Dankner W; Tillotson G
    Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
    Maesen FP; Davies BI; Teengs JP; Baur C
    Eur J Respir Dis Suppl; 1986; 146():585-90. PubMed ID: 3465584
    [No Abstract]   [Full Text] [Related]  

  • 38. Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones?
    Obaji A; Sethi S
    Drugs Aging; 2001; 18(1):1-11. PubMed ID: 11232735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short treatment durations for acute bacterial rhinosinusitis: Five days of gemifloxacin versus 7 days of gemifloxacin.
    Ferguson BJ; Anon J; Poole MD; Hendrick K; Gilson M; Seltzer EG;
    Otolaryngol Head Neck Surg; 2002 Jul; 127(1):1-6. PubMed ID: 12161723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infectious exacerbations of chronic bronchitis: diagnosis and management.
    Sethi S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():97-105. PubMed ID: 10225579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.